Table 2. Overview of Search Process and Studies Incorporated Into Meta-analyses.

Analyzed drug	Enzyme	No. of studies	No. of excluded studies			No. of included studies	No. of individuals by metabolism categorya
			Not dealing with exposure	Incorrect genotyping	No usable data		NMb	IM	PM
Antipsychotics
Aripiprazole	CYP2D6	84	58	4	10	12	814	134	90
Clozapine	CYP2D6	86	78	3	0	5	33	15	4
	CYP2C19						127	65	8
Haloperidol	CYP2D6	109	83	10	3	13	532	158	46
Quetiapine	CYP2D6	45	44	0	0	1	171	0	20
Risperidone	CYP2D6	221	163	9	26	23	1134	186	172
Antidepressants
Amitriptyline	CYP2D6	103	94	1	4	4	43	9	4
	CYP2C19						34	18	6
Escitalopram	CYP2C19	147	135	4	4	4	1110	760	152
Fluoxetine	CYP2D6	313	305	4	1	3	8	0	3
	CYP2C19						71	27	6
Fluvoxamine	CYP2D6	224	212	3	2	7	74	72	0
	CYP2C19						6	6	6
Mirtazapine	CYP2D6	70	59	2	4	5	142	14	19
Nortriptyline	CYP2D6	97	87	3	3	4	28	14	4
Paroxetine	CYP2D6	335	318	8	4	5	89	14	11
Sertraline	CYP2C19	74	68	1	2	3	565	352	40
Venlafaxine	CYP2D6	195	170	5	12	8	509	87	120
	CYP2C19						422	198	21
Total		2103	1874	57	75	94	8379b

Abbreviations: IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer.

^aThe total number of patients is less than the sum of patients for all phenotypes/drugs owing to the fact that CYP2C19 and CYP2D6 genotyping was performed in certain studies.

^bIndicates reference category.